Remove 2023 Remove BioTech Remove Leadership Remove Pharmaceuticals
article thumbnail

EVERSANA Expands Global Commercialisation Capabilities and Strengthens Agency Network with Healthware Group Acquisition

Digital Health Global

The acquisition immediately expands EVERSANA’s European operations and worldwide capabilities to help pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, or solve unique geographic and market-specific challenges.

article thumbnail

Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion

Digital Health Global

The transaction is expected to close in the second half of 2023, subject to receipt of customary regulatory approvals and satisfaction of other customary closing conditions. For the full fourth quarter 2023, Baxter estimates the transaction to result in dilution of approximately $0.10